1. Home
  2. UAN vs REPL Comparison

UAN vs REPL Comparison

Compare UAN & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CVR Partners LP

UAN

CVR Partners LP

HOLD

Current Price

$122.71

Market Cap

1.3B

Sector

Industrials

ML Signal

HOLD

Logo Replimune Group Inc.

REPL

Replimune Group Inc.

HOLD

Current Price

$12.58

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UAN
REPL
Founded
2007
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Agricultural Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.3B
IPO Year
2008
2018

Fundamental Metrics

Financial Performance
Metric
UAN
REPL
Price
$122.71
$12.58
Analyst Decision
Hold
Analyst Count
0
9
Target Price
N/A
★ $5.67
AVG Volume (30 Days)
17.8K
★ 1.8M
Earning Date
04-29-2026
05-21-2026
Dividend Yield
★ 7.91%
N/A
EPS Growth
★ 61.98
N/A
EPS
★ 12.06
N/A
Revenue
★ $606,038,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$10.45
★ N/A
Revenue Growth
★ 15.36
N/A
52 Week Low
$89.20
$1.50
52 Week High
$139.50
$16.33

Technical Indicators

Market Signals
Indicator
UAN
REPL
Relative Strength Index (RSI) 39.08 41.23
Support Level $121.55 $12.40
Resistance Level $138.77 $16.02
Average True Range (ATR) 3.43 0.73
MACD -1.42 -0.22
Stochastic Oscillator 13.51 16.61

Price Performance

Historical Comparison
UAN
REPL

About UAN CVR Partners LP

CVR Partners LP is a manufacturer and supplier of nitrogen fertilizer products. Its principal products include Urea Ammonium Nitrate (UAN) and ammonia. The company market ammonia products to industrial and agricultural customers and UAN products to agricultural customers. The primary geographic markets for its fertilizer products are Kansas, Missouri, Nebraska, Iowa, Illinois, Colorado, and Texas. The company's product sales are heavily weighted toward UAN.

About REPL Replimune Group Inc.

Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.

Share on Social Networks: